Pharmaceuticals

Shifts in market dynamics are challenging the pharmaceutical industry from increasing pricing pressures, the rise of generic and niche products, increasing outsourcing demand and market consolidation, to name a few. A&M helps pharmaceutical companies across their strategic and operational priorities by cutting complexity, accelerating execution and implementing change. A&M’s first-class professionals work with pharmaceutical companies to navigate through this dynamic market to deliver sustainable value creation and growth.

We work with pharmaceuticals companies to deliver:

M&A Strategy, Carve-Outs & Synergy Capture
Strategic Partnerships, Alliances & Joint Ventures
Product Innovation & Launch
Business Unit / Model Re-design
Market Access
Supply Chain Operations
R&D Capabilities and Technology
Quality and Regulatory Compliance
Tech Transfer

We assist various pharmaceutical companies, including those focused on:

Branded & Speciality products
Generics
OTC and Consumer Health products
Contract Research & Manufacturing (CRO, CDMO & CMO)

Thought Leadership

Contract Research Organisations M&A Market

March 28, 2025

Rising cost pressures, stricter regulatory demands and advancements in emerging therapeutics are intensifying competition within the industry. These dynamics are fuelling the demand for greater efficiency in development lifecycles, creating significant opportunities for outsourced providers like Contract Research Organisations (CROs).

Thought Leadership

Healthcare Workforce Predictions for 2025

March 19, 2025

The healthcare landscape in 2025 is marked by a complex interplay of financial pressures, persistent workforce shortages, and rapid technological advancements. While healthcare providers have stabilized post-pandemic, they face shrinking revenues coupled with escalating workforce expense, which now comprise a significant portion of total expenses.

Thought Leadership

Mass General Brigham is Redefining ROI Through the Lens of its Mission to Improve Human Health

March 18, 2025

How do you fundamentally redefine “ROI”? Niyum Gandhi, CFO of Mass General Brigham, the largest employer in New England and the largest medical research organization in the world, shares about his Moonshot to do just that.

Thought Leadership

The Clock is Ticking: Why Health Plans Must Act Now to Maximize Star Ratings Before the 2026 HEI Update

March 12, 2025

The October 2026 Star Ratings release presents both an opportunity and a challenge for health plans as they navigate uncertain Health Equity Index (HEI) changes. With evolving CMS equity-focused metrics, shifting data collection requirements, and potential weighting adjustments, health plans must take immediate action to optimize their Star Ratings before potential regulatory shifts in 2027.